Clinical aspects of visceral leishmaniasis caused by L. infantum in adults. Ten years of experience of the largest outbreak in Europe: what have we learned?

Table 7 Clinical features of IC-VL patients who relapsed

Sex, age (years)	Origin	Sub-Saharan^a	Days to relapse	Drug	Dose (mg/kg)	Retreatment dose (mg/kg)	Status 6 months after retreatment
Male, 38	Spain	No	270	LAB	15	35	Cured
Male, 95	Spain	No	30	LAB	18	30	Cured
Male, 15	Spain	Yes	60	LAB	18	30	Cured
Female, 37	Eq. Guinea	Yes	115	LAB	18	21	Cured
Female, 64	Eq. Guinea	Yes	97	ABLC	21	30 (LAB)	Cured
Male, 34	Eq. Guinea	Yes	165	LAB	21	20 (LAB + miltefosine)	Cured
Male, 39	Nigeria	Yes	71	LAB	21	40	Cured
Male, 51	Spain	No	190	LAB	30	12 (exitus cirrhosis)	Exitus

^aRelapses in persons of sub-Saharan origin with IC-VL: 11.9% (5/42) vs 7.9% (3/38), P = 0.414
Abbreviations: LAB, liposomal B amphotericin; ABLC, amphotericin B lipid complex

ISSN: 1756-3305